{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic%2FAdvanced+Renal+Cell+Carcinoma&page=2", "query": { "condition": "Metastatic/Advanced Renal Cell Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic%2FAdvanced+Renal+Cell+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T10:12:29.199Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00002854", "title": "High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "mesna", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 33, "start_date": "1994-12", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2015-08-26", "last_synced_at": "2026-07-24T10:12:29.199Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002854" }, { "nct_id": "NCT07405086", "title": "Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Advanced Biliary Tract Carcinoma", "Advanced Head and Neck Squamous Cell Carcinoma", "Advanced Hepatocellular Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Renal Cell Carcinoma", "Metastatic Biliary Tract Carcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hepatocellular Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Immune Checkpoint Inhibitor", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2026-06-08", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-07-24T10:12:29.199Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07405086" }, { "nct_id": "NCT00328861", "title": "Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Metastatic Kidney Cancer" ], "interventions": [ { "name": "Natural Killer (NK) Lymphocytes", "type": "DRUG" }, { "name": "IL-2", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2006-05", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2012-11-05", "last_synced_at": "2026-07-24T10:12:29.199Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00328861" }, { "nct_id": "NCT05678673", "title": "Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "XL092", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 317, "start_date": "2023-01-01", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2025-07-14", "last_synced_at": "2026-07-24T10:12:29.199Z", "location_count": 10, "location_summary": "Duarte, California • Newport Beach, California • San Francisco, California + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05678673" }, { "nct_id": "NCT05043090", "title": "Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Papillary Renal Cell Carcinoma" ], "interventions": [ { "name": "savolitinib", "type": "DRUG" }, { "name": "durvalumab", "type": "DRUG" }, { "name": "sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 148, "start_date": "2021-10-28", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-07-24T10:12:29.199Z", "location_count": 2, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05043090" }, { "nct_id": "NCT04963153", "title": "Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Bladder Urothelial Carcinoma", "Locally Advanced Renal Pelvis Urothelial Carcinoma", "Locally Advanced Ureter Urothelial Carcinoma", "Locally Advanced Urethral Urothelial Carcinoma", "Locally Advanced Urothelial Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Renal Pelvis Urothelial Carcinoma", "Metastatic Ureter Urothelial Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Recurrent Bladder Urothelial Carcinoma", "Recurrent Renal Pelvis Urothelial Carcinoma", "Recurrent Ureter Urothelial Carcinoma", "Recurrent Urethral Urothelial Carcinoma", "Recurrent Urothelial Carcinoma", "Stage IIIB Bladder Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Renal Pelvis Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Enfortumab Vedotin", "type": "DRUG" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2022-07-07", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-07-24T10:12:29.199Z", "location_count": 8, "location_summary": "Los Angeles, California • Aurora, Colorado • Tampa, Florida + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04963153" }, { "nct_id": "NCT04953104", "title": "ARID1A and/or KDM6A Mutation and CXCL13 Expression", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Bladder Urothelial Carcinoma", "Locally Advanced Renal Pelvis Urothelial Carcinoma", "Locally Advanced Ureter Urothelial Carcinoma", "Locally Advanced Urethral Urothelial Carcinoma", "Locally Advanced Urothelial Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Renal Pelvis Urothelial Carcinoma", "Metastatic Ureter Urothelial Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Recurrent Bladder Urothelial Carcinoma", "Recurrent Renal Pelvis Urothelial Carcinoma", "Recurrent Ureter Urothelial Carcinoma", "Recurrent Urethral Urothelial Carcinoma", "Recurrent Urothelial Carcinoma", "Stage III Bladder Cancer AJCC v8", "Stage III Renal Pelvis Cancer AJCC v8", "Stage III Ureter Cancer AJCC v8", "Stage III Urethral Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8", "Stage IIIB Bladder Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Renal Pelvis Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Stage IVA Bladder Cancer AJCC v8", "Stage IVB Bladder Cancer AJCC v8", "Unresectable Bladder Urothelial Carcinoma", "Unresectable Renal Pelvis Urothelial Carcinoma", "Unresectable Ureter Urothelial Carcinoma", "Unresectable Urethral Urothelial Carcinoma", "Unresectable Urothelial Carcinoma" ], "interventions": [ { "name": "Diagnostic Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Relatlimab", "type": "DRUG" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-09-21", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-07-24T10:12:29.199Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04953104" }, { "nct_id": "NCT02231749", "title": "Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Renal Cell Carcinoma", "Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1096, "start_date": "2014-10-16", "completion_date": "2025-03-21", "has_results": true, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-07-24T10:12:29.199Z", "location_count": 37, "location_summary": "Duarte, California • La Jolla, California • Los Angeles, California + 28 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02231749" }, { "nct_id": "NCT03091192", "title": "Savolitinib vs. Sunitinib in MET-driven PRCC.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma", "Carcinoma, Renal Cell", "Kidney Neoplasms", "Urologic Neoplasms", "Kidney Diseases", "Neoplasms by Site", "Enzyme Inhibitors", "Protein Kinase Inhibitors" ], "interventions": [ { "name": "Savolitinib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 60, "start_date": "2017-07-25", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-07-24T10:12:29.199Z", "location_count": 8, "location_summary": "La Jolla, California • Atlanta, Georgia • Chicago, Illinois + 5 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03091192" }, { "nct_id": "NCT03024437", "title": "Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Cancer", "Renal Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Entinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roberto Pili", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2017-06-29", "completion_date": "2024-06-24", "has_results": true, "last_update_posted_date": "2025-03-20", "last_synced_at": "2026-07-24T10:12:29.199Z", "location_count": 4, "location_summary": "Indianapolis, Indiana • Columbus, Ohio • Philadelphia, Pennsylvania", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03024437" } ] }